Lupin

Lupin

1,960.50
+9.50
(0.49%)
Market Cap
89,535.15 Cr
EPS
71.95
PE Ratio
27.44
Dividend Yield
0.61 %
Industry
Healthcare
52 Week High
2,402.90
52 Week Low
1,795.20
PB Ratio
5.18
Debt to Equity
0.27
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from34 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+52.94 %
+52.94 %
Hold
Hold+35.29 %
+35.29 %
Sell
Sell+11.76 %
+11.76 %

Company News

View All News
Caret
neutral
Lupin Schedules Q1 FY26 Earnings Call for August 6, 20253 days ago
Lupin Limited has scheduled an earnings call to discuss its Q1 FY26 unaudited financial results on August 6, 2025, at 16:00 hrs IST. The company will conduct the call via Zoom and has provided registration details for participants. The announcement was made by Company Secretary & Compliance Officer Amit Kumar Gupta.
positive
Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products Worth $572 Million4 days ago
Lupin has obtained US FDA approvals for two injectable products - Liraglutide and Glucagon. These approved products have combined total US sales of $572 million, representing a significant market opportunity for the pharmaceutical company's US operations.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,702.20
#1 4,08,414.80
35.57
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
6,584.00
1,74,784.51
80.22
9,712.00
0.89
2,191
23.05
40.37
1,572.00
1,26,971.67
22.93
28,409.50
7.12
5,291
9.88
70.77
3,622.90
1,21,969.00
63.65
11,539.40
6.99
1,911
19.91
72.46
1,287.40
1,07,442.68
#1 18.77
33,741.20
16.73
5,725
1.26
54.50
2,541.60
1,04,899.14
61.83
12,744.20
19.57
2,007
-10.91
52.39
980.10
98,620.99
21.15
23,511.00
13.82
4,615
-0.19
54.96
1,960.50
#8 89,535.15
#5 27.44
#6 22,909.50
#1 19.94
#6 3,306
#1 112.49
53.75
32,895.00
69,899.58
50.72
6,684.70
10.80
1,414
27.83
42.22
1,127.00
65,456.34
18.86
31,378.10
17.55
3,366
-0.50
47.15
Forecast
Actual
Growth Rate
Revenue Growth
19.94 %
Net Income Growth
332.34 %
Cash Flow Change
-17.77 %
ROE
277.31 %
ROCE
143.65 %
EBITDA Margin (Avg.)
75.22 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
3,071
3,157
3,250
3,417
4,144
4,424
4,243
4,511
4,209
3,839
3,952
3,929
4,125
3,960
4,122
3,872
3,922
3,922
4,007
3,844
4,084
3,513
3,807
3,939
3,808
4,265
4,076
4,122
3,880
3,610
4,106
4,263
4,368
4,765
4,980
5,109
4,924
5,582
5,539
5,672
5,619
Expenses
2,289
2,331
2,667
2,702
2,883
3,157
3,260
3,264
3,472
3,104
3,099
3,287
4,789
3,329
3,401
3,608
3,107
3,131
3,788
3,629
3,320
3,040
3,254
3,239
3,066
3,306
5,415
3,791
3,615
3,512
3,693
3,790
3,852
3,958
4,121
4,160
3,964
4,359
4,332
4,412
4,346
EBITDA
783
825
583
715
1,261
1,268
983
1,246
737
735
853
642
-665
631
721
264
814
791
219
215
763
473
553
700
742
960
-1,339
331
265
98
414
473
515
807
859
950
960
1,223
1,207
1,261
1,273
Operating Profit %
25 %
24 %
16 %
19 %
30 %
27 %
23 %
26 %
17 %
18 %
20 %
16 %
-20 %
12 %
13 %
6 %
18 %
18 %
1 %
2 %
12 %
12 %
14 %
17 %
18 %
22 %
-35 %
7 %
6 %
3 %
10 %
11 %
11 %
17 %
17 %
18 %
19 %
21 %
21 %
21 %
22 %
Depreciation
107
101
116
122
149
203
211
231
267
261
272
280
273
259
266
219
219
250
253
253
214
215
213
244
216
209
919
203
327
193
204
220
264
235
248
257
457
248
257
272
393
Interest
3
7
24
10
31
35
29
48
41
44
48
54
59
69
74
79
84
84
83
89
107
44
34
31
32
34
34
33
42
43
55
84
93
86
81
74
71
68
71
67
89
Profit Before Tax
697
792
581
781
1,170
1,156
822
1,045
520
494
611
383
-941
384
441
93
591
518
-54
-73
496
273
360
525
518
751
-2,205
167
-85
2
210
246
259
559
630
736
498
993
1,055
1,071
896
Tax
136
224
158
255
417
273
159
410
137
137
154
161
-163
181
173
245
294
216
70
767
105
164
147
84
54
202
-110
-382
427
89
75
89
16
106
134
117
130
188
195
212
114
Net Profit
561
568
422
526
753
883
663
636
384
357
457
222
-778
203
269
-152
296
303
-123
-840
391
109
214
441
464
548
-2,095
549
-512
-87
135
158
242
453
495
619
368
806
860
859
782
EPS in ₹
12.17
12.65
9.34
11.67
16.63
19.57
14.69
14.04
8.42
7.93
10.07
4.91
-17.33
6.40
5.88
-3.37
6.55
6.69
-2.72
-18.56
8.64
2.36
4.66
9.67
10.15
11.96
-46.22
12.01
-11.40
-1.96
2.85
3.38
5.19
9.94
10.76
13.47
7.89
17.58
18.70
18.75
16.93

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
9,719
Current Assets
7,832
9,887
11,953
12,210
13,854
15,413
13,986
12,458
12,451
13,448
16,799
Capital Work in Progress
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
517
Investments
1,656
16
2,136
262
2,296
2,374
2,455
900
517
1,075
1,146
Other Assets
6,538
11,189
11,305
13,084
12,928
13,732
12,209
12,393
12,846
13,272
17,823
Total Liabilities
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
Current Liabilities
3,729
5,061
6,121
5,096
6,130
9,225
8,436
8,498
9,265
8,502
8,961
Non Current Liabilities
510
6,368
6,955
7,593
8,030
3,178
1,316
1,101
1,148
1,122
2,949
Total Equity
8,898
11,196
13,532
13,617
13,789
12,581
13,858
12,222
12,543
14,374
17,294
Reserve & Surplus
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
17,112
Share Capital
90
90
90
90
91
91
91
91
91
91
91

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1,502
-1,315
2,019
729
-872
1,685
-1,303
87
273
-248
560
Investing Activities
-1,034
-6,769
-2,527
470
-3,283
1,107
-1,240
1,292
-1,287
-1,712
-4,172
Operating Activities
2,733
-382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
3,000
Financing Activities
-197
5,836
433
-1,492
744
-891
-1,885
-1,572
-337
-2,184
1,732

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
46.86 %
46.84 %
46.83 %
46.81 %
46.78 %
47.10 %
47.11 %
47.10 %
47.08 %
47.07 %
47.05 %
47.04 %
47.01 %
46.98 %
46.96 %
46.95 %
46.92 %
46.90 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.11 %
18.28 %
19.32 %
21.50 %
22.04 %
21.46 %
21.25 %
DIIs
22.08 %
21.68 %
24.38 %
24.76 %
26.84 %
26.82 %
27.54 %
29.38 %
29.21 %
28.98 %
29.42 %
29.73 %
27.76 %
26.78 %
25.09 %
24.74 %
25.41 %
25.56 %
Government
0.29 %
0.28 %
0.28 %
0.28 %
0.29 %
0.29 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
10.02 %
9.91 %
10.18 %
9.99 %
8.53 %
8.59 %
8.41 %
8.06 %
7.86 %
7.06 %
6.24 %
5.87 %
5.70 %
5.65 %
5.29 %
5.17 %
5.10 %
5.23 %
Others
20.75 %
21.29 %
18.34 %
18.16 %
17.57 %
17.19 %
16.94 %
15.45 %
15.85 %
16.89 %
17.27 %
1.23 %
1.23 %
1.26 %
1.15 %
1.10 %
1.10 %
1.05 %
No of Share Holders
0
2,93,782
3,02,292
3,61,288
3,61,862
3,78,547
3,82,828
3,78,011
3,60,677
3,22,678
2,89,074
2,81,542
2,80,248
2,88,537
2,79,280
2,81,988
2,83,210
2,86,604

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 7.5 5 5 6 6.5 4 4 8 12
Dividend Yield (%) 0.00 1.02 0.68 0.85 0.59 0.87 0.61 0.25 0.39 0.62

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Aug 2025 1,894.70 1,951.00
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Aug 2025 1,930.85 1,951.00
25 Jul 2025 DIVIDEND Dividend
₹ 12.00 /share
25 Jul 2025 2,063.00 1,943.40
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 2,107.70 2,063.00
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Feb 2025 2,134.25 2,169.40
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 2,151.95 2,166.05
02 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
02 Aug 2024 1,778.90 1,953.55
16 Jul 2024 DIVIDEND Dividend
₹ 8.00 /share
16 Jul 2024 1,655.25 1,832.10
14 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
14 Jul 2023 732.25 930.75
15 Jul 2022 DIVIDEND Dividend
₹ 4.00 /share
14 Jul 2022 683.30 643.20
28 Jul 2021 DIVIDEND Dividend
₹ 6.50 /share
27 Jul 2021 1,212.25 1,111.60

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
Reg. 34 (1) Annual Report.4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication7 days ago
Board Meeting Intimation for Considering And Taking On Record Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.7 days ago
Business Responsibility and Sustainability Reporting (BRSR)8 days ago
Reg. 34 (1) Annual Report.8 days ago
Notice For Forty-Third Annual General Meeting Of The Company And Integrated Report For FY 2024-25.8 days ago
Inspection Of U.S. FDA At The Companys Pithampur Unit-3 Manufacturing Facility.10 days ago
Inspection Of U.S. FDA At The Companys Pithampur Unit-2 Manufacturing Facility.10 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 17, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2025
Intimation Of Record Date For Payment Of Final Dividend If Declared.Jul 14, 2025
Intimation Of The Forty-Third Annual General Meeting Of The Company And Record Date For Payment Of Dividend.Jul 14, 2025
ESG Rating By NSE Sustainability Ratings & Analytics Limited.Jul 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 09, 2025
License And Supply AgreementJul 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 01, 2025
Execution Of Business Transfer Agreement For Transfer Of Its API R&D Division Situated At Pune To Lupin Manufacturing Solutions Limited A Wholly Owned Subsidiary Of The Company On A Slump Sale Basis.Jun 30, 2025
Execution Of Business Transfer Agreement For Transfer Of Its Over-The-Counter Consumer Healthcare Business To LUPINLIFE Consumer Healthcare Limited A Wholly Owned Subsidiary Of The Company On A Slump Sale Basis.Jun 30, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 24, 2025
Intimation Regarding Grant Of Stock Options Under Lupin Employees Stock Option PlansJun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 27, 2025
Announcement under Regulation 30 (LODR)-AllotmentMay 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 23, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 20, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025

Technical Indicators

RSI(14)
Neutral
51.88
ATR(14)
Less Volatile
39.09
STOCH(9,6)
Neutral
61.41
STOCH RSI(14)
Overbought
94.59
MACD(12,26)
Bullish
4.24
ADX(14)
Weak Trend
12.93
UO(9)
Bearish
43.95
ROC(12)
Uptrend And Accelerating
2.97
WillR(14)
Neutral
-30.28

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Invesco India Arbitrage Fund Direct-Growth
1.52%
1459875
1.16%
1.36%
Nippon India Multi Cap Fund Direct-Growth
0.85%
1100798
0.44%
0.38%
UTI Nifty200 Momentum 30 Index Fund Direct - Growth
0.00%
-964155
-2.34%
-2.61%
ICICI Prudential Equity Arbitrage Direct-Growth
0.80%
795175
0.47%
0.52%
HSBC Midcap Fund Direct-Growth
1.54%
-679200
-1.26%
-1.89%
HDFC Multi Cap Fund Direct - Growth
0.61%
586504
0.61%
0.61%
Aditya Birla Sun Life Quant Fund Direct-Growth
0.00%
-397793
-3.17%
-3.41%
HDFC Flexi Cap Direct Plan-Growth
0.73%
300000
0.03%
-0.03%
SBI Arbitrage Opportunities Fund Direct-Growth
0.31%
294525
0.13%
0.16%
Axis ELSS Tax Saver Direct Plan-Growth
0.54%
-284649
-0.18%
-0.24%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.00%
-268175
-0.29%
-0.06%
Quant Multi Cap Fund Direct-Growth
0.45%
237329
0.45%
0.45%
SBI Balanced Advantage Fund Direct - Growth
0.22%
-215900
-0.13%
-0.16%
Nippon India Pharma Fund Direct-Growth
6.07%
200000
0.25%
-0.23%
ICICI Prudential Focused Equity Fund Direct-Growth
3.59%
196817
0.11%
0.45%
Kotak Arbitrage Fund Direct-Growth
0.53%
187000
0.03%
0.34%
Mahindra Manulife Small Cap Fund Direct - Growth
0.00%
-160876
-0.82%
-0.94%
Nippon India ELSS Tax Saver Fund Direct-Growth
0.19%
149432
0.19%
0.19%
HSBC Large and Mid Cap Fund Direct - Growth
0.60%
-124600
-0.62%
-1.22%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-120401
-2.71%
-3.06%
Motilal Oswal Nifty 200 Momentum 30 Index Fund Direct - Growth
0.00%
-109536
-2.34%
-2.61%
Sundaram Mid Cap Fund Direct-Growth
2.28%
108999
0.06%
-0.14%
HDFC ELSS Tax Saver Fund Direct Plan-Growth
0.69%
100000
0.10%
0.04%
Edelweiss Nifty Midcap150 Momentum 50 Index Fund Direct - Growth
1.68%
-96543
-2.12%
-2.62%
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct - Growth
1.68%
-93124
-2.12%
-2.61%

About Lupin

Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Chairperson NameM D Gupta